BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 21692771)

  • 1. A topical combination of rapamycin and tacrolimus for the treatment of angiofibroma due to tuberous sclerosis complex (TSC): a pilot study of nine Japanese patients with TSC of different disease severity.
    Wataya-Kaneda M; Tanaka M; Nakamura A; Matsumoto S; Katayama I
    Br J Dermatol; 2011 Oct; 165(4):912-6. PubMed ID: 21692771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First left-right comparative study of topical rapamycin vs. vehicle for facial angiofibromas in patients with tuberous sclerosis complex.
    Tanaka M; Wataya-Kaneda M; Nakamura A; Matsumoto S; Katayama I
    Br J Dermatol; 2013 Dec; 169(6):1314-8. PubMed ID: 23909960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The mTOR inhibitor rapamycin significantly improves facial angiofibroma lesions in a patient with tuberous sclerosis.
    Hofbauer GF; Marcollo-Pini A; Corsenca A; Kistler AD; French LE; Wüthrich RP; Serra AL
    Br J Dermatol; 2008 Aug; 159(2):473-5. PubMed ID: 18547304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Topical Rapamycin in Patients With Facial Angiofibromas Secondary to Tuberous Sclerosis Complex: The TREATMENT Randomized Clinical Trial.
    Koenig MK; Bell CS; Hebert AA; Roberson J; Samuels JA; Slopis JM; Tate P; Northrup H;
    JAMA Dermatol; 2018 Jul; 154(7):773-780. PubMed ID: 29800048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of current data on the use of topical rapamycin in the treatment of facial angiofibromas in tuberous sclerosis complex.
    Balestri R; Neri I; Patrizi A; Angileri L; Ricci L; Magnano M
    J Eur Acad Dermatol Venereol; 2015 Jan; 29(1):14-20. PubMed ID: 25174683
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Effects of Topical 0.2% Sirolimus for Angiofibromas in Adults and Pediatric Patients with Tuberous Sclerosis Complex.
    Lee YI; Lee JH; Kim DY; Chung KY; Shin JU
    Dermatology; 2018; 234(1-2):13-22. PubMed ID: 29925060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful treatment of angiofibromata of tuberous sclerosis complex with rapamycin.
    Kaufman McNamara E; Curtis AR; Fleischer AB
    J Dermatolog Treat; 2012 Feb; 23(1):46-8. PubMed ID: 20673154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Topical rapamycin: a novel approach to facial angiofibromas in tuberous sclerosis.
    Haemel AK; O'Brian AL; Teng JM
    Arch Dermatol; 2010 Jul; 146(7):715-8. PubMed ID: 20644030
    [No Abstract]   [Full Text] [Related]  

  • 9. Topical 0.1% rapamycin for angiofibromas in paediatric patients with tuberous sclerosis: a pilot study of four patients.
    Foster RS; Bint LJ; Halbert AR
    Australas J Dermatol; 2012 Feb; 53(1):52-6. PubMed ID: 22309333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel topical rapamycin cream for the treatment of facial angiofibromas in tuberous sclerosis complex.
    Wheless JW; Almoazen H
    J Child Neurol; 2013 Jul; 28(7):933-6. PubMed ID: 23680945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapamycin as a therapy of choice after renal transplantation in a patient with tuberous sclerosis complex.
    Tarasewicz A; Debska-Slizień A; Konopa J; Zdrojewski Z; Rutkowski B
    Transplant Proc; 2009 Nov; 41(9):3677-82. PubMed ID: 19917366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sustained clinical effectiveness and favorable safety profile of topical sirolimus for tuberous sclerosis - associated facial angiofibroma.
    Salido R; Garnacho-Saucedo G; Cuevas-Asencio I; Ruano J; Galán-Gutierrez M; Vélez A; Moreno-Giménez JC
    J Eur Acad Dermatol Venereol; 2012 Oct; 26(10):1315-8. PubMed ID: 21834948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of facial angiofibromas with topical application of oral rapamycin solution (1mgmL(-1) ) in two patients with tuberous sclerosis.
    Mutizwa MM; Berk DR; Anadkat MJ
    Br J Dermatol; 2011 Oct; 165(4):922-3. PubMed ID: 21692776
    [No Abstract]   [Full Text] [Related]  

  • 14. Tuberous Sclerosis Complex in 29 Children: Clinical and Genetic Analysis and Facial Angiofibroma Responses to Topical Sirolimus.
    Wang S; Liu Y; Wei J; Zhang J; Wang Z; Xu Z
    Pediatr Dermatol; 2017 Sep; 34(5):572-577. PubMed ID: 28771801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Topical Sirolimus Therapy for Facial Angiofibromas in the Tuberous Sclerosis Complex : A Randomized Clinical Trial.
    Wataya-Kaneda M; Nakamura A; Tanaka M; Hayashi M; Matsumoto S; Yamamoto K; Katayama I
    JAMA Dermatol; 2017 Jan; 153(1):39-48. PubMed ID: 27837201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy and safety of topical rapamycin-calcitriol for facial angiofibromas in patients with tuberous sclerosis complex: a prospective, double-blind, randomized clinical trial.
    Chen PL; Hong JB; Shen LJ; Chen YT; Wang SJ; Liao YH
    Br J Dermatol; 2020 Oct; 183(4):655-663. PubMed ID: 32064596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Facial angiofibromas associated to tuberous sclerosis treated with topical sirolimus].
    Tiedemann Svendsen M; Bygum A; Hansen LK; Broesby-Olsen S
    Ugeskr Laeger; 2013 Oct; 175(43):2569-70. PubMed ID: 24629155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapamycin therapy for renal, brain, and skin lesions in a tuberous sclerosis patient.
    Micozkadioglu H; Koc Z; Ozelsancak R; Yildiz I
    Ren Fail; 2010; 32(10):1233-6. PubMed ID: 20954988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Topical rapamycin for angiofibromas in paediatric patients with tuberous sclerosis: follow up of a pilot study and promising future directions.
    Tu J; Foster RS; Bint LJ; Halbert AR
    Australas J Dermatol; 2014 Feb; 55(1):63-9. PubMed ID: 24359523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sirolimus Gel Treatment vs Placebo for Facial Angiofibromas in Patients With Tuberous Sclerosis Complex: A Randomized Clinical Trial.
    Wataya-Kaneda M; Ohno Y; Fujita Y; Yokozeki H; Niizeki H; Ogai M; Fukai K; Nagai H; Yoshida Y; Hamada I; Hio T; Shimizu K; Murota H
    JAMA Dermatol; 2018 Jul; 154(7):781-788. PubMed ID: 29800026
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.